undetectable. However, it could be due to the sensitivity of HA-tag/anti-HA Ab. Although they served a control, its expression could be very high. It will be ideal if the authors insert V5-tag to Tet3 and compare the expression levels of Tet1/2/3 in parallel with the same tag/Ab system. 2. To verify the hypothesis of the functional interaction between Nanog and Tet2, the authors reanalyzed the published data of ChIP-seq. Do the Tet2 binding depend on Nanog in these cooccupied sites? It could be assessed bt ChIP-seq of Tet2 in Nanog-null ES cells. 3. The proportion of the merge between Nanog and Tet2 should be quantified by FACS or other method. 4. What is the significance of the kinetics of Tet expressions during the transition of ES cells to the primed state? The transition happen in few days in normal development whereas it takes much longer in culture dish.
Referee #3 Review
Received: 1st Aug 19 Report for Author:
In this manuscript Pantier et al, investigated the expression of the TET1, TET2 and TET3 in mouse ESCs. They do this by tagging the endogenous Tet genes using CRISPR/Cas9 in ESCs. Then they evaluated at the single cell level the expression of the TET proteins using FACS and IF, finding that TET1 is expressed in the naïve and primed state, whereas TET2 is mostly expressed in the naïve state. They finally showed that TET2 interacts with Nanog.
The ESCs generated could be of interest for the stem cell field as a tool and probably the epigenetic field as well, as the authors showed in several assays the utility of them.
The experiments are mostly well performed (please see some of the comments). However, I do not find that the manuscript provides any strong biological insight into pluripotency biology. The expression of the TET family in ESC (naï ve and primed) has being described before, where KD, ChiP and RNA has been well described. Several manuscript s have shown the RNA levels of the TET family (t he aut hors do not find differences bet ween the expression of prot ein and RNA). Indeed, the aut hors used ChIP-seq from a previously published paper where TET2 was det ect ed (on this not e: using previously published dat a is great , but remarks that is not novel the presence of TET2 in ESCs).
Thus, I believe that as a manuscript describing a new tool is a good manuscript (please two comment s below to improve the manuscript ) however it lacks biological insight . I believe that the following suggest ions may improve the charact erisat ion of the cells that the aut hors have generat ed.
1) The pluripotency of the targeted cells should be tested. 2) I would recommend that mass spec is performed in the tagged ESCs to validate the presence of the tagged TETs. This could be done in the sorted + and -populations. 1st Editorial Decision Thank you for transferring your manuscript entitled "Identification of TET2 as a naïve pluripotency marker by comprehensive epitope-tagging of Tet1, Tet2 and Tet3 alleles" to Life Science Alliance. The manuscript was assessed by expert reviewers at another journal before, and the editors transferred those reports to us with your permission.
The reviewers who assessed your manuscript elsewhere before appreciated the high quality of the work, but would have expected more functional insight. This concern does not preclude publication in Life Science Alliance, and we would thus like to invite you to submit a revised version of your manuscript for publication here. We would expect a point-by-point response to all concerns raised. You already provided an outline of how you would respond to the issues raised upfront, and we think that your responses as well as the proposed quantification and self-renewing assay addresses the reviewer concerns sufficiently. So please proceed as planned.
To upload the revised version of your manuscript, please log in to your account: https://lsa.msubmit.net/cgi-bin/main.plex You will be guided to complete the submission of your revised manuscript and to fill in all necessary information. Please get in touch in case you do not know or remember your login name.
While you are revising your manuscript, please also attend to the below editorial points to help expedite the publication of your manuscript. Please direct any editorial questions to the journal office.
The typical timeframe for revisions is three months.
Thank you for this interesting contribution to Life Science Alliance. We are looking forward to receiving your revised manuscript.
Sincerely,
Andrea Leibfried, PhD Executive Editor Life Science Alliance Meyerhofstr. 1 69117 Heidelberg, Germany t +49 6221 8891 502 e a.leibfried@life-science-alliance.org www.life-science-alliance.org
A. THESE ITEMS ARE REQUIRED FOR REVISIONS
--A letter addressing the reviewers' comments point by point.
--An editable version of the final text (.DOC or .DOCX) is needed for copyediting (no PDFs).
--High-resolution figure, supplementary figure and video files uploaded as individual files: See our detailed guidelines for preparing your production-ready images, http://www.life-sciencealliance.org/authors --Summary blurb (enter in submission system): A short text summarizing in a single sentence the study (max. 200 characters including spaces). This text is used in conjunction with the titles of papers, hence should be informative and complementary to the title and running title. It should describe the context and significance of the findings for a general readership; it should be written in the present tense and refer to the work in the third person. Author names should not be mentioned.
B. MANUSCRIPT ORGANIZATION AND FORMATTING:
Full guidelines are available on our Instructions for Authors page, http://www.life-sciencealliance.org/authors
We encourage our authors to provide original source data, particularly uncropped/-processed electrophoretic blots and spreadsheets for the main figures of the manuscript. If you would like to add source data, we would welcome one PDF/Excel-file per figure for this information. These files will be linked online as supplementary "Source Data" files. ***IMPORTANT: It is Life Science Alliance policy that if requested, original data images must be made available. Failure to provide original images upon request will result in unavoidable delays in publication. Please ensure that you have access to all original microscopy and blot data images before submitting your revision.***
We are pleased that the reviewers generally appreciate our tagging strategy to visualise TET proteins and think that our cell lines would be useful reagents for the scientific community. We note that all reviewers are happy with the quality of our data. We respond to specific reviewer's points below:
Referee #1:
In this report, Chambers and colleagues addressed an important question about TETs and resolved their role in naive vs primed states. The evidence presented are very strong and support the general conclusion. Furthermore, this will allow further studies to be carried out by others to establish DNA demethylation in naive pluripotent cells.
We are pleased that this reviewer appreciates the value of our efforts.
Referee #2:
In this manuscript, the authors reported the expression patterns of Tet enzymes (Tet1/2/3) in mouse embryonic stem (ES) cells. Because of the lack of good antibodies for immunostaining, they applied the knock-in strategy to add the different epitope tags to the endogenous Tet genes with the Crispr/Cas9 system. As the result, they established the ES cell line in which all Tet enzymes are labeled with epitope tags. Using this cell line and the control lines, they found that Tet2 expression is heterogeneous and lost after the conversion to the primed state. They revealed that the Tet2 expression is largely merged to the Nanog expression and they interact directly. From these findings, they hypothesized that Tet2 and Nanog may cooperate to regulate ES-specific enhancers. The function of Tet enzymes in ES cells has been well analyzed. Dawlaty et al reported that Tet2 KO ES cells are fully pluripotent since they efficiently contribute to chimeric embryos after blastocyst injection, suggesting its dispensable role (Dev Cell, 2013) .
TET2 is dispensable for pluripotency/self-renewal (Dawlaty et al., 2013 and our unpublished data) . This is why we refer to TET2 in our manuscript title as a "marker" rather than a master regulator of self-renewing ESCs.
Therefore, the hypothetical function of the cooperation between Tet2 and Nanog might not be important to maintain pluripotency. For the interaction between Nanog and Tet enzymes, Costa et al demonstrated that Tet1 directly interact with Nanog and Tet2 has overlapping function with Tet1 for synergistic action with Nanog in reprogramming of somatic cells to pluripotent state althouth the direct interaction was not reported for Nanog and Tet2 (Nature, 2013), weakening the novelty of the finding shown in this manuscript. The weakness of this manuscript is the lack of the functional data that makes it quite descriptive. It is little bit below for the publication in EMBO Rep.
Our main aim was to generate ESC lines carrying tagged Tet1/2/3 alleles and perform detailed characterisation of TET protein expression in pluripotent cells as this had not been done properly in past studies, due to the lack of reliable antibodies for TET1/2/3. We discovered that TET2 protein expression is heterogeneous in ESCs cultured in serum/LIF and is tightly associated with the self-renewing capacity of ESCs. This novel functional data intersects well with our recent studies on the functional significance of ESRRB heterogeneity (Festuccia et al., EMBO J 2018) .
1. For the expression of tet3, the authors introduced HA-tag and found that its expression is undetectable. However, it could be due to the sensitivity of HA-tag/anti-HA Ab. Although they served a control, its expression could be very high. It will be ideal if the authors insert V5-tag to Tet3 and compare the expression levels of Tet1/2/3 in parallel with the same tag/Ab system.
Using our tagged ESC line, we find that TET3 expression is undetectable by immunofluorescence (Figure 1, panel B ). We used a commercial antibody which presents a high affinity for the HA epitope-tag: Santa Cruz Y-11, cat. sc-805. Tet3 transcripts are very low with levels 50-times lower than Tet1 and 10-times lower than Tet2, respectively, in ESCs cultured in serum/LIF ( Supplementary Figure 6 , panels A and B). Our results with HA-Tet3 are therefore consistent with mRNA studies and our conclusions are unlikely to be altered by performing the V5-Tet3 tagging analysis.
2. To verify the hypothesis of the functional interaction between Nanog and Tet2, the authors re-analyzed the published data of ChIP-seq. Do the Tet2 binding depend on Nanog in these co-occupied sites? It could be assessed by ChIP-seq of Tet2 in Nanog-null ES cells.
A recent study reported that TET2 could be efficiently ChIPed only after extensive crosslinking with "formaldehyde + DSG" (Rasmussen et al, 2019) , suggesting that TET2 interacts indirectly with chromatin. TET2 localises to completely different loci in ESCs and hematopoietic cells (Rasmussen et al, 2019) , supporting a model in which TET2 is targeted to chromatin via protein-protein interactions in a context-dependent manner. This is consistent with the fact that TET2 does not have a DNA binding domain. Therefore, one might expect transcription factors, such as NANOG to target TET2 to pluripotency enhancers. We amended the Discussion of our manuscript (p.12, second paragraph) to better reflect this point. SOX2 has also been reported to physically interact with TET2 (Zhu et al, 2014) . As there are many studies showing an overlap in chromatin binding sites for Nanog and Sox2 (Chen, et al. 2008; Kim et al. 2008 are the cornerstone papers), it is possible that TET2 can be targeted to chromatin also by Sox2, and may do so even in Nanog-null cells. Therefore, it is not straightforward to think that deletion of Nanog would give the clean outcome the reviewer predicts. So, while we agree that the reviewer's suggestion is indeed an interesting one, we consider this to be beyond the scope of the present study.
3. The proportion of the merge between Nanog and Tet2 should be quantified by FACS or other method.
In our study, we report that TET2 is heterogeneously expressed in ESCs cultured in serum/LIF and correlates with NANOG expression by co-immunofluorescence (Figure 3 , panel A). An additional line of evidence in favour of a positive correlation between NANOG and TET2 is that FACS-sorted TET2-positive ESCs are significantly enriched for Nanog transcripts compared to TET2-negative ESCs (Figure 2, panel D) . As the reviewer requests, we have now quantitated the number of cells that have negative, single-and double-positive NANOG/TET2 nuclei. This data is presented as a new panel in Figure 3 (panel B) and shows, in line with our prior conclusions, that the majority of cells that express TET2 also express NANOG.
4. What is the significance of the kinetics of Tet expressions during the transition of ES cells to the primed state? The transition happen in few days in normal development whereas it takes much longer in culture dish.
We used two different protocols to model the transition out of naïve pluripotency: EpiSC (Guo et al, 2009) and EpiLC (Hayashi et al, 2011) . Stable EpiSC lines are obtained after multiple passages (Figure 4 and Supplementary Figure 12) whereas ESCs homogenously differentiate into EpiLC after only 48h (Figure 4 and Supplementary Figure 13) . The reviewer states that "transition happen in few days in normal development whereas it takes much longer in culture". However, this is only true for EpiSCs as the transition times in vivo and for EpiLCs are similar. Importantly, TET2 expression was consistently lost in both EpiLCs and EpiSCs (Figure 4, panels B and C) .
Referee #3:
In this manuscript Pantier et al, investigated the expression of the TET1, TET2 and TET3 in mouse ESCs. They do this by tagging the endogenous Tet genes using CRISPR/Cas9 in ESCs. Then they evaluated at the single cell level the expression of the TET proteins using FACS and IF, finding that TET1 is expressed in the naïve and primed state, whereas TET2 is mostly expressed in the naïve state. They finally showed that TET2 interacts with Nanog. The ESCs generated could be of interest for the stem cell field as a tool and probably the epigenetic field as well, as the authors showed in several assays the utility of them. The experiments are mostly well performed (please see some of the comments). However, I do not find that the manuscript provides any strong biological insight into pluripotency biology. The expression of the TET family in ESC (naïve and primed) has being described before, where KD, ChiP and RNA has been well described. Several manuscripts have shown the RNA levels of the TET family (the authors do not find differences between the expression of protein and RNA). Indeed, the authors used ChIP-seq from a previously published paper where TET2 was detected (on this note: using previously published data is great, but remarks that is not novel the presence of TET2 in ESCs).
Thus, I believe that as a manuscript describing a new tool is a good manuscript (please two comments below to improve the manuscript) however it lacks biological insight.
To our knowledge, most of the data regarding the expression of TET family genes in pluripotent cells (or other cell types) correspond to RNA levels. Even though it may not be surprising that RNA and protein expression correlate quite well, this is a novel discovery. Moreover, assessing the expression of TET proteins in single cells by immunofluorescence and FACS allowed us to reveal the heterogeneity of TET2 expression in ESCs. This novel finding allowed us to perform subsequent experiments which linked TET2 to self-renewal and naïve pluripotency. We also believe that our tagged ESC lines will constitute useful reagents for the scientific community as they will allow further biochemical characterisation of TET family proteins using high-affinity epitope tag antibodies (for ChIP, IP-mass spec, etc.) .
I believe that the following suggestions may improve the characterisation of the cells that the authors have generated. 1)
The pluripotency of the targeted cells should be tested. Figure 1 ). The two main cell lines used in this study are "Tet tag/tag " (Figures 1 and 4) and "Tet2 Flag-IRES-EGFP " (Figures 2 and 3) ESCs. "Tet2 Flag-IRES-EGFP " ESCs retain expression of the pluripotency factor NANOG ( Figure 3A) . We have now added similar analyses showing that "Tet1 V5/V5 " and "Tet tag/tag " ESCs also retain expression of NANOG (Supplementary Figure  8B,C) . "Tet2 Flag-IRES-EGFP " ESCs have a similar self-renewing capacity as wild-type ESCs ( Figure 2C ). We have now performed a similar self-renewal assay in "Tet1 V5/V5 " and "Tet tag/tag " ESCs (Supplementary Figure 8A) . This shows that both lines retain a proportionally similar self-renewal capacity to E14Tg2a ESCs.
All our targeted ESC lines are derived from pluripotent E14Tg2a ESCs (see Supplementary
2) I would recommend that mass spec is performed in the tagged ESCs to validate the presence of the tagged TETs. This could be done in the sorted + and -populations.
In all our ESC lines, correct targeting was verified by PCR genotyping. In particular, we also checked that the TET coding sequence was in-frame with the added epitope tag by Sanger sequencing of the Tet alleles (and we can provide these, if necessary). We therefore consider MS (while interesting) is unnecessary as a "validation" procedure. 1st Revision -Editorial Decision If you are planning a press release on your work, please inform us immediately to allow informing our production team and scheduling a release date.
To upload the final version of your manuscript, please log in to your account: https://lsa.msubmit.net/cgi-bin/main.plex You will be guided to complete the submission of your revised manuscript and to fill in all necessary information. Please get in touch in case you do not know or remember your login name.
To avoid unnecessary delays in the acceptance and publication of your paper, please read the following information carefully.
A. FINAL FILES:
These items are required for acceptance.
--High-resolution figure, supplementary figure and video files uploaded as individual files: See our detailed guidelines for preparing your production-ready images, http://www.life-sciencealliance.org/authors --Summary blurb (enter in submission system): A short text summarizing in a single sentence the study (max. 200 characters including spaces). This text is used in conjunction with the titles of papers, hence should be informative and complementary to the title. It should describe the context and significance of the findings for a general readership; it should be written in the present tense and refer to the work in the third person. Author names should not be mentioned.
B. MANUSCRIPT ORGANIZATION AND FORMATTING:
We encourage our authors to provide original source data, particularly uncropped/-processed electrophoretic blots and spreadsheets for the main figures of the manuscript. If you would like to add source data, we would welcome one PDF/Excel-file per figure for this information. These files will be linked online as supplementary "Source Data" files.
**Submission of a paper that does not conform to Life Science Alliance guidelines will delay the acceptance of your manuscript.** **It is Life Science Alliance policy that if requested, original data images must be made available to the editors. Failure to provide original images upon request will result in unavoidable delays in publication. Please ensure that you have access to all original data images prior to final submission.** **The license to publish form must be signed before your manuscript can be sent to production. A link to the electronic license to publish form will be sent to the corresponding author only. Please take a moment to check your funder requirements.** **Reviews, decision letters, and point-by-point responses associated with peer-review at Life Science Alliance will be published online, alongside the manuscript. If you do want to opt out of having the reviewer reports and your point-by-point responses displayed, please let us know immediately.** Thank you for your attention to these final processing requirements. Please revise and format the manuscript and upload materials within 7 days.
Thank you for this interesting contribution, we look forward to publishing your paper in Life Science Alliance.
Sincerely, Andrea Leibfried, PhD Executive Editor Life Science Alliance Meyerhofstr. 1 69117 Heidelberg, Germany t +49 6221 8891 502 e a.leibfried@life-science-alliance.org www.life-science-alliance.org
Referee #2:
Using our tagged ESC line, we find that TET3 expression is undetectable by immunofluorescence (Figure 1, panel B) . We used a commercial antibody which presents a high affinity for the . Tet3 transcripts are very low with levels 50-times lower than Tet1 and 10-times lower than Tet2, respectively, in ESCs cultured in serum/LIF ( Supplementary Figure 6, panels A and B) . Our results with HA-Tet3 are therefore consistent with mRNA studies and our conclusions are unlikely to be altered by performing the V5-Tet3 tagging analysis.
In our study, we report that TET2 is heterogeneously expressed in ESCs cultured in serum/LIF and correlates with NANOG expression by co-immunofluorescence (Figure 3,  panel A) . An additional line of evidence in favour of a positive correlation between NANOG and TET2 is that FACS-sorted TET2-positive ESCs are significantly enriched for Nanog transcripts compared to TET2-negative ESCs (Figure 2, panel D) . As the reviewer requests, we have now quantitated the number of cells that have negative, single-and double-positive NANOG/TET2 nuclei. This data is presented as a new panel in Figure 3 (panel B) and shows, in line with our prior conclusions, that the majority of cells that express TET2 also express NANOG.
Referee #3:
I believe that the following suggestions may improve the characterisation of the cells that the authors have generated.
1) The pluripotency of the targeted cells should be tested.
All our targeted ESC lines are derived from pluripotent E14Tg2a ESCs (see Supplementary  Figure 1 ). The two main cell lines used in this study are "Tet tag/tag " (Figures 1 and 4) and "Tet2 Flag-IRES-EGFP " (Figures 2 and 3) ESCs. "Tet2 Flag-IRES-EGFP " ESCs retain expression of the pluripotency factor NANOG ( Figure 3A) . We have now added similar analyses showing that "Tet1 V5/V5 " and "Tet tag/tag " ESCs also retain expression of NANOG (Supplementary Figure  8B,C) . "Tet2 Flag-IRES-EGFP " ESCs have a similar self-renewing capacity as wild-type ESCs ( Figure 2C ). We have now performed a similar self-renewal assay in "Tet1 V5/V5 " and "Tet tag/tag " ESCs (Supplementary Figure 8A) . This shows that both lines retain a proportionally similar self-renewal capacity to E14Tg2a ESCs.
In all our ESC lines, correct targeting was verified by PCR genotyping. In particular, we also checked that the TET coding sequence was in-frame with the added epitope tag by Sanger sequencing of the Tet alleles (and we can provide these, if necessary). We therefore consider MS (while interesting) is unnecessary as a "validation" procedure.
